SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.International journal of clinical oncology · 2017Pooled it
- The diagnostic accuracy of HE4 in lung cancer: a meta-analysis.Disease markers · 2015Pooled it
- Diagnosis and Surgical Management for Advanced Pancreatic Cancer Requiring Vascular Resection.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnostic Stratification of Pancreatic Ductal Adenocarcinoma via Metallomics and Blood-Based Biomarkers.Diagnostics (Basel, Switzerland) · 2025Article
- Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.BMC medicine · 2025Article
- An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment.The British journal of radiology · 2025Review
- Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects.Biomarker research · 2023Review
- Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer.Clinical epigenetics · 2023Article
- Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study.BMC gastroenterology · 2023Article
- Article
- Article
- A nomogram diagnostic prediction model of pancreatic metastases of small cell lung carcinoma based on clinical characteristics, radiological features and biomarkers.Frontiers in oncology · 2022Article
- Retrospective Analysis of the Value of Enhanced CT Radiomics Analysis in the Differential Diagnosis Between Pancreatic Cancer and Chronic Pancreatitis.International journal of general medicine · 2022Article
- Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma.Journal of Cancer · 2022Article
- Diagnostic Impact of Radiological Findings and Extracellular Vesicles: Are We Close to Radiovesicolomics?Biology · 2021Review
- Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.Journal of molecular biology · 2021Article
- Systematic appraisal of guidelines for the diagnosis of pancreatic cancer.Gland surgery · 2021Review
- Review
- Transcriptome analysis identifies putative multi-gene signature distinguishing benign and malignant pancreatic head mass.Journal of translational medicine · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly malignant cancer with increasing incidence and mortality worldwide. Carbohydrate antigen 19-9 (CA19-9) has been widely reported to play a role in the diagnosis of pancreatic cancer patients. However, published data on this subject are inconclusive. There was no meta-analysis that has been previously performed to evaluate critically the diagnostic accuracy of CA19-9 for pancreatic cancer. Therefore, we performed a meta-analysis to evaluate the sensitivity and specificity of CA19-9 in the diagnosis of pancreatic cancer. We conducted a comprehensive search to identify studies in which the pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operating curves (SROC) could be determined. A total of 11 studies that included 2,316 individuals who fulfilled all of the inclusion criteria were considered for analysis. The summary estimates for serum CA19-9 in the diagnosis of pancreatic cancer in these studies were pooled sensitivity 0.80 (95 % confidence interval [CI] 0.77-0.82), specificity 0.80 (95 % CI 0.77-0.82), and DOR 14.79 (95 % CI 8.55-25.59), and the area under the curve was 0.87. Our meta-analysis showed that serum CA19-9 plays important role in the diagnosis of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.